GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform

Can RNAi Work In The Lung?

 
• By Andrew McConaghie
  
Arrowhead
Arrowhead is hoping for proof-of-concept data in lung disease and cholesterol lowering candidates in Q2. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapy Areas